Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?

References

• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Hyjek E, Vardiman JW. Myelodysplastic/myeloproliferative neoplasms. Semin Diagn Pathol. 2011;28:283–297.
   PubMed Web of Science ®Google Scholar
• Dinmohamed AG, Brink M, Visser O, et al. Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012. Br J Haematol. 2015;171:436–439.
   PubMed Web of Science ®Google Scholar
• Osca-Gelis G, Puig-Vives M, Saez M, et al. Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993–2007. Leuk Res. 2012;36:1262–1266.
   PubMed Web of Science ®Google Scholar
• Hafraoui K, De Prijck B, Beguin Y. [Chronic myelomonocytic leukemia: from diagnosis to treatment]. Revue Medicale Suisse. 2013;9:1512,1514–1517.
   Google Scholar
• Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28:3858–3865.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27:1441–1450.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Chronic inflammation as a promoter of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37:214–220.
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–759.
   PubMed Web of Science ®Google Scholar
• Landskron G, De la Fuente M, Thuwajit P, et al. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899.
   PubMed Web of Science ®Google Scholar
• Skov V, Thomassen M, Riley CH, et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol. 2012;40:771–780.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013;121:2186–2198.
   PubMed Web of Science ®Google Scholar
• Barosi G. An immune dysregulation in MPN. Curr Hematol Malig Rep. 2014;9:331–339.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Landgren O, Samuelsson J, et al. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010;95:1216–1220.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29:2897–2903.
   PubMed Web of Science ®Google Scholar
• Braun T, Fenaux P. Myelodysplastic syndromes (MDS) and autoimmune disorders (AD): cause or consequence? Best Pract Res Clin Haematol. 2013;26:327–336.
   PubMed Web of Science ®Google Scholar
• Deniz Peker EP, Pedro H, Bennett JM, et al. A close association of history of autoimmunity with chronic myelomonocytic leukemia (CMML) in contrast to chronic myelogenous leukemia (CML). Blood (Suppl). 2012;120:Abstract 1712.
   Google Scholar
• Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2002;43:2083–2092.
   PubMed Web of Science ®Google Scholar
• Isoda A, Sakurai A, Ogawa Y, et al. Chronic inflammatory demyelinating polyneuropathy accompanied by chronic myelomonocytic leukemia: possible pathogenesis of autoimmunity in myelodysplastic syndrome. Int J Hematol. 2009;90:239–242.
   PubMed Web of Science ®Google Scholar
• Espinosa G, Font J, Munoz-Rodriguez FJ, et al. Myelodysplastic and myeloproliferative syndromes associated with giant cell arteritis and polymyalgia rheumatica: a coincidental coexistence or a causal relationship? Clin Rheumatol. 2002;21:309–313.
   PubMed Web of Science ®Google Scholar
• Enright H, Miller W. Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma. 1997;24:483–489.
   PubMed Web of Science ®Google Scholar
• Hamidou MA, Boumalassa A, Larroche C, et al. Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. Semin Arthritis Rheu. 2001;31:119–126.
   PubMed Web of Science ®Google Scholar
• Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51–60.
   PubMed Web of Science ®Google Scholar
• Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011;96:752–761.
   PubMed Web of Science ®Google Scholar
• Landgren O, Engels EA, Caporaso NE, et al. Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood 2006;108:292–296.
   PubMed Web of Science ®Google Scholar
• Landgren O, Gridley G, Check D, et al. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol. 2007;139:791–798.
   PubMed Web of Science ®Google Scholar
• Lindholm SA, Hasselbalch HC. Smoking and philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol. 2015. [Epub ahead of print]. DOI: 10.1111/ejh.12684.
   Web of Science ®Google Scholar
• Peker D, Padron E, Bennett JM, et al. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2015;133:249–256.
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Michel M, Chauveheid MP, et al. Immune thrombocytopenia in chronic myelomonocytic leukemia. Eur J Haematol. 2014;93:521–526.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Pemmaraju N, Strati P, et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood. 2013;122:2807–2811.
   PubMed Web of Science ®Google Scholar
• Rosenthal NS, Farhi DC. Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Am J Clin Pathol. 1996;106:676–679.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012;119:3219–3225.
   PubMed Web of Science ®Google Scholar
• Peters T, Weiss JM, Sindrilaru A, et al. Reactive oxygen intermediate-induced pathomechanisms contribute to immunosenescence, chronic inflammation and autoimmunity. Mech Ageing Dev 2009;130:564–587.
   PubMed Web of Science ®Google Scholar
• Tong H, Hu C, Yin X, et al. A meta-analysis of the relationship between cigarette smoking and incidence of myelodysplastic syndromes. PLoS One. 2013;8:e67537.
   PubMed Web of Science ®Google Scholar
• Goncalves RB, Coletta RD, Silverio KG, et al. Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm Res. 2011;60:409–424.
   PubMed Web of Science ®Google Scholar
• Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest. 2007;131:1557–1566.
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27:2084–2086.
   PubMed Web of Science ®Google Scholar
• Eaton WW, Rose NR, Kalaydjian A, et al. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007;29:1–9.
   PubMed Web of Science ®Google Scholar
• Padron E, Painter JS, Kunigal S, et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013;121:5068–5077.
   PubMed Web of Science ®Google Scholar
• Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011;117:2690–2696.
   PubMed Web of Science ®Google Scholar
• Thorpe M, Montalvao A, Pierdomenico F, et al. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res. 2012;36:1071–1073.
   PubMed Web of Science ®Google Scholar